Medications

Wegovy vs Zepbound: Which Weight Loss Injection Works Better?

Nuvo Health Team · 9 min read

Quick answer

Wegovy (semaglutide) and Zepbound (tirzepatide) are both FDA-approved weekly injections for chronic weight management. Clinical trials show Zepbound produces more weight loss on average, but both have strong evidence behind them. Here's a detailed comparison to help you and your provider decide.

Wegovy and Zepbound are the two leading prescription injectable medications for chronic weight management in the United States. Both require a weekly subcutaneous injection, both cause significant appetite suppression, and both have been shown to produce substantial weight loss in large clinical trials. But they are not the same drug — and the differences matter.

How Each Drug Works

Wegovy (semaglutide 2.4 mg) works by mimicking GLP-1, a hormone that signals fullness to the brain, slows stomach emptying, and reduces food intake. GLP-1 agonists have been used to treat type 2 diabetes for years; Wegovy is the higher-dose formulation approved specifically for weight management.

Zepbound (tirzepatide) activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP receptors are expressed in fat tissue, the brain, and the gut. The dual agonism appears to amplify appetite suppression and calorie reduction beyond what GLP-1 activation alone achieves. This dual-mechanism design is why tirzepatide was developed as the "next generation" after semaglutide.

Weight Loss Results: What the Trials Show

Both drugs have been studied in large, placebo-controlled trials, and both show results far exceeding lifestyle intervention alone. The headline numbers:

Wegovy (STEP 1 trial, 68 weeks, non-diabetic adults): average weight loss of 14.9% of body weight at the highest dose (2.4 mg)
Zepbound (SURMOUNT-1 trial, 72 weeks, non-diabetic adults): average weight loss of 20.9% at the highest dose (15 mg)
Placebo (both trials): approximately 2–3% weight loss

These numbers come from separate trials with different participant populations and slightly different study lengths, so a direct comparison between trial results requires caution. The more rigorous comparison comes from a head-to-head trial.

The Head-to-Head Trial: SURMOUNT-5

SURMOUNT-5 was a randomized, double-blind trial that directly compared tirzepatide versus semaglutide 2.4 mg in adults with obesity or overweight and at least one weight-related comorbidity. After 72 weeks:

Tirzepatide (5–15 mg dose range): mean body weight reduction of approximately 20.2%
Semaglutide 2.4 mg: mean body weight reduction of approximately 13.7%
The difference was statistically significant, with tirzepatide demonstrating roughly 47% more relative weight loss

This head-to-head data is important: it confirms that tirzepatide produces more weight loss on average than semaglutide at their respective approved doses in a comparable population. However, "on average" hides individual variation. Some patients lose more weight on semaglutide than others lose on tirzepatide, and vice versa.

Side Effects: How Similar Are They?

Because both drugs affect gut hormones and slow gastric emptying, their side effect profiles are closely related. The most common side effects for both Wegovy and Zepbound include:

Nausea: The most frequently reported side effect for both, especially in the first 4–12 weeks. Usually decreases as the body adjusts.
Diarrhea: Common with both, particularly after dose increases.
Constipation: Paradoxically common; affects some users more than diarrhea.
Vomiting: Less frequent than nausea but possible, especially during escalation.
Abdominal discomfort: Bloating, fullness, or stomach pain can occur.
Decreased appetite: A desired effect that can become problematic if it prevents adequate nutrition.

Both drugs carry the same FDA boxed warning about the risk of thyroid C-cell tumors observed in animal studies. Neither should be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2. Both also require monitoring for pancreatitis, gallbladder disease, and heart rate changes.

Clinical trials did not show a significant difference in the rate of serious adverse events between tirzepatide and semaglutide. Anecdotally, some patients report tolerating one drug better than the other — this is worth discussing with your provider if you've tried one and had difficulty.

Dosing and Injection

Both are weekly subcutaneous injections given in the abdomen, thigh, or upper arm. The titration schedules differ:

Wegovy: Starts at 0.25 mg weekly for 4 weeks, titrates every 4 weeks through 0.5 mg, 1 mg, 1.7 mg, to a maintenance dose of 2.4 mg weekly (total 16-week titration)
Zepbound: Starts at 2.5 mg weekly for 4 weeks, then increases by 2.5 mg every 4 weeks up to a maximum of 15 mg weekly (up to 20-week titration to reach maximum dose)
Wegovy uses a single-dose auto-injector pen; Zepbound uses the KwikPen auto-injector or single-dose vials with a separate syringe

Cost and Insurance Coverage

Cost is often the deciding factor between these two drugs, because pharmacy and insurance formulary decisions vary significantly by plan.

List price: Both Wegovy and Zepbound cost approximately $1,000 to $1,350 per month at retail without insurance or manufacturer discount programs.
With insurance: Coverage depends entirely on your plan. Some plans cover one but not the other. Many employer-sponsored plans exclude weight loss medications entirely.
Savings cards: Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) both offer manufacturer savings cards that can significantly reduce out-of-pocket cost for commercially insured patients who qualify.
Eligibility criteria: Both typically require a BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. Prior authorization is common for both.

Which One Should You Choose?

The honest answer is that the "better" drug is whichever one you can afford, tolerate, and stay on long term. That said, here's how to think about it:

If maximum weight loss potential is your priority and cost is similar: Zepbound (tirzepatide) has shown superior weight loss in head-to-head data.
If your insurance covers Wegovy but not Zepbound: Wegovy still produces meaningful weight loss (average ~15%) and has a longer track record in clinical use.
If you've already tried one and didn't lose enough weight: Consider switching. Some patients who respond modestly to semaglutide respond better to tirzepatide, and the reverse is also possible.
If you have type 2 diabetes: Ozempic (semaglutide) and Mounjaro (tirzepatide) are the diabetes-indicated versions of these drugs. Your provider will factor in blood sugar management alongside weight loss when choosing.
If you've had GI side effects on one drug: It's not guaranteed that switching will reduce them — both drugs share similar GI mechanisms — but some patients do tolerate one better than the other.

Frequently Asked Questions

Is Wegovy or Zepbound stronger?

In clinical trials, Zepbound produces more weight loss on average. The SURMOUNT-5 head-to-head trial found tirzepatide users lost approximately 47% more weight relative to semaglutide users. However, individual responses vary, and "stronger" doesn't mean it's the right choice for every person.

Can I switch from Wegovy to Zepbound?

Yes, switching is possible. Your provider will typically establish an appropriate starting dose for Zepbound based on where you are in your Wegovy treatment. There's no required washout period between the two drugs, though your provider may choose a conservative titration approach when switching.

Do Wegovy and Zepbound work the same way?

They overlap but are not identical. Both activate GLP-1 receptors, which is why their side effect profiles are similar. Zepbound additionally activates GIP receptors, which is believed to be the reason it produces more weight loss. Think of Zepbound as a GLP-1 agonist plus an additional mechanism, not simply a stronger GLP-1 agonist.

What happens if I stop taking either medication?

Both drugs require long-term use to maintain their effects. Clinical data consistently shows that most patients regain a significant portion of lost weight after discontinuing treatment. This is not a personal failing — it reflects the underlying biology of appetite regulation. These are chronic disease treatments, similar to how blood pressure medications must be taken long-term to maintain their effects.

This article is for informational purposes only. Both Wegovy and Zepbound are prescription medications. Consult your healthcare provider to determine which medication, if any, is appropriate for your individual health situation.